Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM- CSF) products in patients undergoing combination therapy with GM-CSF

Clinical Cancer Research

Volumn 5, Issue 6, 1999, Pages 1353-1361

  Wadhwa, Meenu ^a   Skog, Anna Lena Hjelm ^b   Bird, Chris ^a   Ragnhammar, Peter ^b   Lilljefors, Maria ^b   Gaines Das, Rose ^a   Mellstedt, Hakan ^b   Thorpe, Robin ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; EOSINOPHIL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; LEUKOCYTE; NEUTROPHIL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BINDING, COMPETITIVE; COLORECTAL NEOPLASMS; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; IMMUNOBLOTTING; INTERLEUKIN-2; LEUKOCYTE COUNT; MIDDLE AGED;

EID: 0033052121     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Morrissey, P., Bressler, L., Park, L., Alpert, A., and Gillis, S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen presenting cells. J. Immunol., 139: 1113-1119, 1987.
2. Vadas, M., Nicola, N., and Metcalf, D. Activation of antibody dependent cell mediated cytotoxicity of human neutrophils and eosinophils by separate colony stimulating factors. J. Immunol., 130: 795-799, 1983.
3. Masucci, P., Wersall, P., Ragnhammar, P., and Mellstedt, H. Granulocyte monocyte colony stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother., 29: 288-292, 1989.
4. Gamble, J. R., Elliott, M. J., Jaipargas, E., Lopez, A. F., and Vadas, M. A. Regulation of human monocyte adherence by granulocyte-macrophage colony-stimulating factor. Proc. Natl. Acad. Sci. USA, 86: 7169-7173, 1989.
5. Arnaout, M., Wang, E., Clark, S., and Sieff, C. Human recombinant granulocyte macrophage colony stimulating factor increases cell to cell adhesion and surface expression of adhesion promoting glycoproteins on mature granulocytes. J. Clin. Invest., 78: 597-601, 1986.
6. Hill, A., Redmond, H., Austin, O., Grace, P., and Bouchier-Hayes, D. Granulocyte-macrophage colony-stimulating factor inhibits tumor growth. Br. J. Surg., 80: 1543-1546, 1993.
7. Charak, B., Agah, R., and Mazumder, A. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation. Blood, 81: 3474-3479, 1993.
8. Hooijberg, E., Sein, I., van den Berk, P. C., Hart, A. A., van der Valk, M. A., Kast, W. M., Melief, C. J., and Hekman, A. Eradication of large human B-cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin-2. Cancer Res., 55: 2627-2634, 1995.
9. Ragnhammar, P., Frodin, J. E., Trotta, P. P., and Mellstedt, H. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies. Cancer Immunol. Immunother., 39: 254-262, 1994.
10. Ragnhammar, P., Friesen, H. J., Frodin, J. E., Lefvert, A. K., Hassan, M., Osterborg, A., and Mellstedt, H. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in non-immunocompromised patients. Blood, 84: 4078-4087, 1994.
11. Gribben, J. G., Devereux, S., Thomas, N. S. B., Keim, M., Jones, H. M., Goldstone, A. H., and Linch, D. C. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet, 335: 434-437, 1990.
12. Thompson, J. A., Lee, D. J., Kidd, P., Rubin, E., Kaufman, J., Bonnem, E. M., and Fefer, A. Subcutaneous granulocyte macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity pharmacokinetics and hematological effects. J. Clin. Oncol., 7: 629-637, 1989.
13. Kirkwood, T. B. L. Geometric means and measures of dispersion. Biometrics, 35: 908-909, 1979.
14. Kitamura, T., Tange, T., Terasawa, T., Chiba, S., Kuwaki, T., Miyagawa, K., Piao, Y. F., Miyazono, K., Urabe, A., and Takaku, F. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol., 140: 323-334, 1989.
15. Wadhwa, M., Bird, C., Page, L. A., Mire-Sluis, A. R., and Thorpe, R. Quantitative biological assays for individual cytokines. In: F. R. Balkwill (eds.), Cytokines: A Practical Approach, Ed. 2, pp. 357-391. Oxford: IRL Press, 1995.
16. Johnstone, A. P., and Thorpe, R. Immunochemistry in Practice, Ed. 3, pp. 211-226. Oxford, England: Blackwell Scientific, 1997.
17. ab fragments. Gene (Amst.), 141: 79-84, 1994.
18. Wadhwa, M., Bird, C., Fagerberg, J., Gaines-Das, R., Ragnhammar, P., and Mellstedt, H. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin. Exp. Immunol., 104: 351-358, 1996.
19. Laricchia-Robbio, L., Moscato, S., Genua, A., Liberati, A. M., and Revoltella, R. P. Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum. J. Cell Physiol., 173: 219-226, 1997.
20. Steis, R. G., Smith, J. W., Urba, W. J., Clark, J. W., Itri, L. M., Evans, L. M., Schoenberger, C., and Longo, D. L. Resistance to recombinant interferon α-2a in hairy-cell leukaemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med., 318: 1409-1413, 1988.
21. Steis, R., and Longo, D. Clinical relevance of recombinant interferon-α2a antibodies in patients with hairy cell leukaemia. J. Interferon Res., 14: 207-209, 1994.
22. Antonelli, G., Giannelli, G., Pistello, M., Maggi, F., Vatteroni, L., Currenti, M., Del Vecchio, S., Roffi, L., Pastore, G., and Dianzani, F. Clinical significance of recombinant interferon-α2a neutralizing antibodies in hepatitis patients. J. Interferon Res., 14: 211-213, 1994.
23. Antonelli, G., Currenti, M., Turriziani, O., and Dianzani, F. Neutralizing antibodies to interferon-α: relative frequency in patients treated with different interferon preparations. J. Infect. Dis., 163: 882-885, 1991.
24. + chronic myeloid leukaemia sequentially treated with recombinant (α2a) and lymphoblastoid interferon-α. Br. J. Haematol., 94: 300-305, 1996.
25. Ronnblom, L. E., Tiensuujanson, E., and Peters, A. Characterization of anti-interferon-α antibodies appearing during recombinant interferon-α2a treatment. Clin. Exp. Immunol., 89: 330-335, 1992.
26. Oberg, K. Autoimmunity and antibodies to interferons in patients with carcinoid tumors: clinical consequences. J. Interferon Res., 14: 215-217, 1994.
27. Hanley, J. P., Jarvis, L. M., Simmonds, P., and Ludlam, C. A. Development of anti-interferon antibodies and breakthrough hepatitis during treatment for HCV infection in haemophiliacs. Br. J. Haematol., 94: 551-556, 1996.
28. McKenna, R. M., and Oberg, K. E. Antibodies to interferon-α in treated cancer patients: incidence and significance. J. Interferon Cytokine Res., 17: 141-143, 1997.
29. Itri, L. M., Sherman, M. I., Palleroni, A. V., Evans, L. M., Tran, L. L., Campion, M., and Chizzonite, R. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-α2a. J. Interferon Res., 9: S9-S15, 1989.
30. Galton, J. E., Bedford, P., and Scott, J. E. Antibodies to lymphoblastoid interferon. Lancet, ii: 572-573, 1989.
31. Ahlers, J. D., Dunlop, N., Alling, D. W., and Berzofsky, J. A. Cytokine in adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF α synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J. Immunol., 158: 3947-3958, 1997.
32. Disis, M. L., Bernhard, H., Shiota, F. M., Hand, S. L., Gralow, J. R., Huseby, E. S., Gillis, S., and Cheever, M. A. Granulocyte-macrophage colony stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood, 88: 202-210, 1996.
33. Burgess, A. W., Begley, C. G., Johnson, G. R., Lopez, A. F., Williamson, D. J., Mermod, J. J., Simpson, R. J., Schmitz, A., and DeLamarter, J. F. Purification and properties of bacterially synthesized human granulocyte-macrophage colony stimulating factor. Blood, 69: 43-51, 1987.
34. DeLamarter, J. F., Mermod, J. J., Liang, C. M., Eliason, J. F., and Thatcher, D. R. Recombinant murine GM-CSF from E. coli has biological activity and is neutralized by a specific antiserum. EMBO J., 4: 2575-2581, 1985.